Navigation Links
Nationwide survey reveals differing physician and patient perceptions regarding impact of UC
Date:12/7/2007

Aventura, FL December 7, 2007 Nearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate this to be true for only 37 percent of their UC patients, according to results from a nationwide series of surveys presented today at the 2007 Crohns & Colitis Foundations 6th Annual Advances in the Inflammatory Bowel Diseases conference.

The series of surveys, titled UC: NORMAL (New Observations on Remission Management and Lifestyle), were sponsored by Shire Pharmaceuticals, a specialty biopharmaceutical company, which markets once-daily LIALDA and PENTASA (mesalamines) for UC.

Before these surveys, patient and physician views on UCs impact had not been compared and the real-life impact of UC had not been explored to this extent, says lead author David Rubin, MD, a gastroenterologist and associate professor of medicine at the University of Chicago Medical Center who helped design the surveys. This series of surveys brings to light some challenges for the UC community: patients accept a high level of disruption from UC on their lives; physician and patient views regarding the impact of UC are not in alignment; and compliance with medications requiring multiple daily dosing is a challenge."

The UC: NORMAL surveys were fielded online between February and March 2007. For the physician survey, doctors were recruited by fax from a complete list of US board-certified gastroenterologists. Gastroenterologists who spent less than half their time in direct patient care were excluded from the study.

At the time the surveys were fielded (prior to the availability of a once-daily mesalamine), patients reported they found it difficult to adhere to medication dosing schedules. Forty-six percent of patients (n=451) reported they had not taken all of their medication in the past week and 41 percent of gastroenterologists (n=300) believed their patients were not adheri
'/>"/>

Contact: Blythe Bertolo
bbertolo@golinharris.com
312-729-4463
Shire plc
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
2. Joint NJ/NY Rally for Addiction Recovery to Be Hub of Events Nationwide
3. Photo: Tanger Outlet Center Shoppers Nationwide can Choose Pink to Fight Breast Cancer
4. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
5. Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During America on the Move Week With the YMCA, September 22-29, 2007
6. NIH/NCI renews and extends nationwide license for Genomatix software and databases
7. 100 Black Men of America, Inc. and American Red Cross Sign National Agreement to Increase Diverse Outreach Nationwide
8. New Website Launches Healthy Vending in Schools Nationwide to Help Combat Childhood Obesity
9. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
10. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
11. Nationwide independent Taser study results suggest devices are safe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... Steven Reinberg HealthDay ... New guidelines from the American Diabetes Association (ADA) call for ... with diabetes to help prevent heart disease. These new ... of Cardiology and American Heart Association, which also recommend giving ... heart disease, including people with diabetes. "We agree that ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 24, 2014 ... COC Industry is a professional and in-depth research ... the report introduces COC basic information, including its ... policy analysis, news analysis, etc. This report also ... structure etc. Production is separated by regions, technology ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... ATLANTA, Sept. 23 The Hospital of Central Connecticut (THOCC), ... IM Practice Manager to automate, organize and increase quality of ... physicians at THOCC will be using IM,s handheld and Internet-based solution, ... users, making it the most widely used electronic charge capture system ...
... , SALT LAKE CITY, Sept. 23 Dynatronics Corporation ... quarter and year ended June 30, 2009 during the morning of Friday, ... its third consecutive quarter of profitability. , , Dynatronics ... p.m. ET to discuss its results for the quarter and year periods. ...
... , , ROCHESTER, N.Y., Sept. 23 ... R. Kerry Clark and Robert J. Palmisano have joined its board ... outstanding business leaders with broad and relevant experience," said Gerald M. ... these help us become better positioned for long-term growth. We welcome ...
... Foundation recently received a $1 million planned-gift donation ... radiology fellows to pursue this medical profession. SIR ... of interventional radiology by specializing in developing investigators ... research. "This enormously generous gift supports the ...
... Washington DC (September23, 2009) SAGE is partnering with the ... in 2010. A peer-reviewed quarterly journal, Cartilage will ... many types of researchers and clinicians involved in cartilage biology ... Cartilage is edited by Roy D. Altman, M.D., ...
... H1N1 influenza could slow growth in key industries and ... of 2009, says a health economist in the University of ... travel are vitally important sectors in the economy of many ... severity of the spread of the virus, consumers and businesses ...
Cached Medicine News:Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 2Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 3Health News:R. Kerry Clark and Robert J. Palmisano Join Bausch & Lomb Board of Directors 2Health News:Society of Interventional Radiology Foundation receives $1 million legacy gift 2Health News:Swine flu could wreak more havoc on US economy, says UAB economist 2
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Inc. (Nasdaq: BNVI ) announced today that it will ... 2009 ended September 30, 2009 on Thursday, November 5, 2009. ... to review the financial results on Thursday, November 5, 2009 ... call by dialing (800) 860-2442 or (412) 858-4600, or can ...
... October 29 Amsterdam Molecular,Therapeutics (AMT) and Progenika Biopharma ... and commercialization agreement for,LPLchip(TM), a diagnostic tool to rapidly ... AMT has developed Glybera(R) as,a gene therapy for patients ... June of this year AMT announced new clinical data ...
Cached Medicine Technology:AMT Starts Development LPLChip(TM) With Progenika 2AMT Starts Development LPLChip(TM) With Progenika 3